Egan Dwight H 4
4 · Co-Diagnostics, Inc. · Filed May 28, 2024
Insider Transaction Report
Form 4
Egan Dwight H
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Common Stock
2024-05-23$1.09/sh−42,008$45,789→ 367,206 total - Exercise/Conversion
Restricted Stock Unit
2024-05-23−138,333→ 627,500 totalExercise: $0.00→ Common Stock (765,833 underlying) - Award
Common Stock
2024-05-23+138,333→ 409,214 total
Footnotes (2)
- [F1]Included in 125,000 restricted stock units awarded to the Reporting Person on August 12, 2021, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2021. Included in 275,000 restricted stock units awarded to the Reporting Person on June 6, 2022, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2022. Included in 155,000 restricted stock units awarded to the Reporting Person on January 17, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on May 23, 2023. Included in 275,000 restricted stock units awarded to the Reporting Person on May 15, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2023.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSU's. This sale is mandated by the Issuer's election, under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.